{
  "docId": "019de074-2557-77dc-997c-34813158de99",
  "docSlug": "5df8d2698ec92d4699700c9c99264cb6",
  "documentTitle": "Alkermes | Investor Presentation Deck | 28 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 28,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "key_messages",
  "function": "establish_context",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Includes a boxed warning disclaimer at the bottom.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-2557-77dc-997c-34813158de99/7",
  "deckHref": "/decks/019de074-2557-77dc-997c-34813158de99",
  "deckJsonHref": "/decks/019de074-2557-77dc-997c-34813158de99.json",
  "deckAnchorHref": "/decks/019de074-2557-77dc-997c-34813158de99#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.87
      },
      "kind": "disclaimer",
      "text": "Boxed Warning: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. LYBALVI is not approved for the treatment of patients with dementia-related psychosis. Full prescribing information may be found at www.lybalvi.com/lybalvi-prescribing-information.pdf",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f50d626-3b38-4883-9514-e2c40c91e88c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.315,
        "w": 0.415,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bd736b68-68fe-4c20-87fa-2fa8a350bc2c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.48,
        "x": 0.48,
        "y": 0.28
      },
      "kind": "list",
      "text": "Once-daily, oral atypical antipsychotic composed of olanzapine, an established antipsychotic agent, and samidorphan, a new chemical entity. Commercially launched in U.S. Q4 2021 with differentiated label. Indicated for the treatment of: Schizophrenia in adults. Bipolar I disorder in adults: Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate. Maintenance monotherapy treatment.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b910448e-282d-4a98-b642-b7a2db536b1d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "LYBALVI® (olanzapine and samidorphan): Oral Treatment Option for Adults With Schizophrenia or Bipolar I Disorder",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa1decec-7def-4b97-8cda-92a86c4c8700",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 12,
      "from": 7,
      "beatId": "6d35d34e-b7cc-496c-bea5-417850fd8b1c",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The deck presents LYBALVI as a solution with strong launch traction.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 12,
      "from": 7,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "03ac4acb-09ea-4723-97d7-19dbedfde939",
      "evidence": "The deck presents LYBALVI's prescription growth trends and market sizing.",
      "position": 0,
      "objective": "What are the key features and benefits of LYBALVI?",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.6,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}